Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
about
Apatinib for molecular targeted therapy in tumorEfficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysisMulticenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.A case report of apatinib in treating osteosarcoma with pulmonary metastases.Elemene injection induced autophagy protects human hepatoma cancer cells from starvation and undergoing apoptosis.Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancerSuccessful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case reportThe Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of LiteratureTherapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage.Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancerSuccessful treatment with apatinib for refractory recurrent malignant gliomas: a case series.DKK4 enhances resistance to chemotherapeutics 5-Fu and YN968D1 in colorectal cancer cells.Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects.Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.Apatinib for the treatment of gastric cancer.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis.Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.Advanced alveolar soft part sarcoma responds to apatinib.Successful treatment of angiosarcoma of the scalp with apatinib: a case report.Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature reviewApatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case reportResponse to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China.Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report.Apatinib has anti-tumor effects and induces autophagy in colon cancer cells.Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study.Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System.
P2860
Q26775828-11D4F566-06E6-4441-BA12-9B078D643897Q28079362-1795F6E6-9C8F-4CFE-830F-055EDED36946Q33413742-FEEB3AC4-8377-4670-A14D-110965DA80BDQ33597266-82C1A6EB-2562-4EAB-8CA8-555BC343FF7EQ34054522-9122B5C5-E943-403B-A6ED-A8AD838043B1Q34544166-32150147-D37D-4760-82C1-043D64A641F8Q34675903-75C80142-FED1-431A-97D3-D8689F3EE94CQ36993067-CB96406E-2E26-4D79-B24B-084BC8ABD236Q37082827-741833CF-CD7D-43AD-8B85-557FC8B4937BQ37086246-7760D791-B50B-4907-A04C-9AF62D051AA1Q37108209-4A97BE56-6A36-4304-B251-79B57A204690Q37653025-07E8E111-8C84-425D-9826-F78E624B75D3Q37701103-74FDABC2-DD8E-4263-9D46-3D18B36C8E07Q37705643-15CCA4F4-44AF-487F-B2C7-2CDD144A90CCQ37921797-4ED85655-3A6C-4E0A-A3C1-1954878655C4Q38210070-3CDB8DFD-2901-4460-9B4B-D83BED1E71ECQ38270899-F5328CB2-7942-4797-A2D4-D550069835A5Q38552109-45417D17-03AE-4D54-9B5B-E6088B750FDCQ38578404-7CFC8B74-3355-4F5A-9705-376B95B925D7Q38635603-2D446A7F-EE6D-4A89-B9C8-88ABA66D836EQ38759141-88F8E6D3-3410-409E-87DD-7F91FF698884Q38760954-D0EB668F-E68C-4AFA-8BF8-DD7B6CCDA688Q38826507-04B9C4B9-122A-4365-BB91-6A2EDDCCA594Q39366121-196E72D3-51D6-4366-8B89-29252AF5C05BQ39455675-8613650F-A010-4295-ACC4-B624383410B0Q39569400-8F9DF32D-69DD-4476-BF55-4830361895B9Q39630965-FD6CEF01-36EF-419D-931A-C0285A79B01AQ40058691-B57C49AF-9715-43C7-B368-8FFBFB90A2C2Q41473058-D31B45C2-DA66-469C-BCDF-9D85140FD1BAQ41753175-701BC47E-D9B3-4B29-A5A5-1E3DA4B151AEQ41915464-38B03C04-9B5C-48C1-8E4B-185BF5F3C999Q42289797-A25FA921-8B9A-4AAC-A880-9FF40D00D835Q42317538-91B171E8-24BF-42F1-AC71-4422258085DAQ42362795-B54A1C1A-3127-404A-BC93-EFCD26461820Q45711840-37D3130F-723F-4604-B10C-D7E862F8616CQ47115888-D705EFC2-1371-402B-BBA2-330632487AA9Q47130946-4B93ABDD-9961-4DB3-ADAF-785EA0AE255EQ47174386-A464B141-B713-4260-9731-E9DF5DFEC5DEQ47339196-7FF7BF1C-D924-467B-B422-EFE39D49BA96Q47423570-830E4C17-C828-463B-A652-A2F1CAFA5F37
P2860
Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Safety and pharmacokinetics of ...... nts with advanced malignancies
@ast
Safety and pharmacokinetics of ...... nts with advanced malignancies
@en
Safety and pharmacokinetics of ...... nts with advanced malignancies
@en-gb
Safety and pharmacokinetics of ...... nts with advanced malignancies
@nl
type
label
Safety and pharmacokinetics of ...... nts with advanced malignancies
@ast
Safety and pharmacokinetics of ...... nts with advanced malignancies
@en
Safety and pharmacokinetics of ...... nts with advanced malignancies
@en-gb
Safety and pharmacokinetics of ...... nts with advanced malignancies
@nl
prefLabel
Safety and pharmacokinetics of ...... nts with advanced malignancies
@ast
Safety and pharmacokinetics of ...... nts with advanced malignancies
@en
Safety and pharmacokinetics of ...... nts with advanced malignancies
@en-gb
Safety and pharmacokinetics of ...... nts with advanced malignancies
@nl
P2093
P2860
P3181
P356
P1433
P1476
Safety and pharmacokinetics of ...... nts with advanced malignancies
@en
P2093
Chunlei Zheng
Fangfang Lv
Fengqing Wang
Xinmin Zhao
P2860
P2888
P3181
P356
10.1186/1471-2407-10-529
P407
P50
P577
2010-01-01T00:00:00Z
P5875
P6179
1033427036